HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes

T-cell-based immunotherapies are promising treatments for cancer patients. Although durable responses can be achieved in some patients, many patients fail to respond to these therapies, underscoring the need for improvement with combination therapies. From a screen of 850 bioactive compounds, we ide...

Descripción completa

Detalles Bibliográficos
Autores principales: Mbofung, Rina M., McKenzie, Jodi A., Malu, Shruti, Zhang, Min, Peng, Weiyi, Liu, Chengwen, Kuiatse, Isere, Tieu, Trang, Williams, Leila, Devi, Seram, Ashkin, Emily, Xu, Chunyu, Huang, Lu, Zhang, Minying, Talukder, Amjad H., Tripathi, Satyendra C., Khong, Hiep, Satani, Nikunj, Muller, Florian L., Roszik, Jason, Heffernan, Timothy, Allison, James P., Lizee, Gregory, Hanash, Sam M., Proia, David, Amaria, Rodabe, Davis, R. Eric, Hwu, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587668/
https://www.ncbi.nlm.nih.gov/pubmed/28878208
http://dx.doi.org/10.1038/s41467-017-00449-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587668/
https://www.ncbi.nlm.nih.gov/pubmed/28878208
http://dx.doi.org/10.1038/s41467-017-00449-z

Ejemplares similares